Overall, the immunohistochemistry data further confirmed the interaction between HDAC1, RXRα, and HtrA1, and suggested that HtrA1, especially in combination with HDAC1, may be used as a predictive biomarker for platinum treatment response and prognosis in patients with NSCLC. Here, HTRA1 is linked to non-small cell lung carcinoma.